Reproducibility of the Diagnosis of Diabetes Over a 30-Month Follow-Up
The Paris Prospective Study
- Eveline Eschwège, MD,
- Marie Aline Charles, MD,
- Dominique Simon, MD,
- Nadine Thibult, MSC and
- Beverley Balkau, PHD
Abstract
OBJECTIVE—To describe the change in diabetic status over 30 months.
RESEARCH DESIGN AND METHODS—Cohort study of 5,400 Caucasian men from the Paris Prospective Study, aged 44–55 years, who were not known as having diabetes at baseline. Oral glucose tolerance tests were performed at baseline and after 30 months.
RESULTS—At baseline, diabetes was diagnosed in 2.9% of the men by fasting plasma glucose (FPG) ≥7.0 mmol/l and in 0.9% by isolated postchallenge hyperglycemia (IPH) (FPG <7.0 mmol/l and 2-h plasma glucose concentration ≥11.1 mmol/l), i.e., one in four of all men with newly diagnosed diabetes. Thirty months later, 42% of the men with diabetes diagnosed by FPG reverted to nondiabetic status, compared with 72% of those with diabetes diagnosed by IPH (P < 0.0001). For the men with diabetes diagnosed by FPG at baseline, diabetes had been diagnosed by a physician at 30 months in 11.5%, in contrast to only 3.9% of those with diabetes diagnosed by IPH (P < 0.05). For the 51 men with diabetes diagnosed by IPH at baseline, those who reverted to nondiabetic status had a lower frequency of family history of diabetes (P < 0.1), a higher mean corpuscular volume (P < 0.08), and a significantly higher total cholesterol concentration (P < 0.006) at baseline; in contrast, for the 156 men with diabetes diagnosed by FPG at baseline, the men who reverted to nondiabetic status and those who remained diabetic had similar characteristics.
CONCLUSIONS—In this epidemiological study, diabetes diagnosed by one FPG concentration was more stable than diabetes diagnosed by one IPH; in clinical practice, the diagnosis of diabetes requires confirmation of the hyperglycemia.
- FPG, fasting plasma glucose
- IFG, impaired fasting glucose
- IGT, impaired glucose tolerance
- IPH, isolated postchallenge hyperglycemia
- WHO, World Health Organization
Footnotes
-
Address correspondence and reprint requests to Eveline Eschwège, MD, INSERM Unit 258, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif, France. E-mail: eschwege{at}vjf.inserm.fr.
Received for publication 2 November 2000 and accepted in revised form 5 July 2001.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.














